eukaryotic translation initiation factor 3 (Synonyms: H2N-Asn-Leu-Gln-Leu-Leu-Met-Asp-Arg-Val-OH ) |
| Katalog-Nr.GP10039 |
Eukaryotic translation initiator
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Eukaryotic initiation factors (eIF) are proteins involved in the initiation phase of eukaryotic translation. eIF3 binds to the ribosome subunit-mRNA complex. It has been implicated in preventing the large ribosomal subunit from binding the small subunit before it is ready to commence elongation. In mammals, eIF3 is the largest scaffolding initiation factor, made up of 13 subunits (a-m). It is roughly ~750 kDa and it controls the assembly of40S ribosomal subunit on mRNA that have a 5' cap or an IRES (Internal Ribosomal Entry Site). eIF3 uses the eIF4F complex or IRES from viruses to position the mRNA strand near the exit site of the 40S ribosome subunit, thus promoting the assembly of the pre-initiation complex.[1]
PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. [2]. Amplification of EIF3S3 gene is common in late-stage prostate cancersuggesting that it may be functionally involved in the progression of the disease [3]. Recent study shows that eukaryotic translation initiation factor 3 subunit 3 does not seem to be overrepresentedindependent of c-myc in prostate cancer [4].
References:
1. Umadas Maitra, Jayanta Chaudhuri; Jayanta Chaudhuri, Kausik Si (21). "Function of Eukaryotic Translation Initiation Factor 1A (eIF1A) (Formerly Called eIF-4C) in Initiation of Protein Synthesis". The Journal of BIological Chemistry 272 (12): 7883-7891. doi:10.1074/jbc.272.12.7883. Retrieved 19 February 2012.
2. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Okamoto, H., Yasui, K., Zhao, C., Arii, S., Inazawa, J. Hepatology (2003)
3. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Saram?ki, O., Willi, N., Bratt, O., Gasser, T.C., Koivisto, P., Nupponen, N.N., Bubendorf, L., Visakorpi, T. Am. J. Pathol. (2001)
4. Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Tsuchiya, N., Kondo, Y., Takahashi, A., Pawar, H., Qian, J., Sato, K., Lieber, M.M., Jenkins, R.B. Am. J. Pathol. (2002)
| Cas No. | SDF | ||
| Überlieferungen | H2N-Asn-Leu-Gln-Leu-Leu-Met-Asp-Arg-Val-OH | ||
| Canonical SMILES | NC(CC(N)=O)C(NC(CC(C)C)C(NC(CCC(N)=O)C(NC(CC(C)C)C(NC(CC(C)C)C(NC(CCSC)C(NC(CC(O)=O)C(NC(CCCNC(N)=N)C(NC(C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
| Formula | C47H84N14O14S | M.Wt | 1101.32 |
| Löslichkeit | ≥110.1mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.908 mL | 4.54 mL | 9.08 mL |
| 5 mM | 0.1816 mL | 0.908 mL | 1.816 mL |
| 10 mM | 0.0908 mL | 0.454 mL | 0.908 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *